JP5945532B2 - グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 - Google Patents
グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 Download PDFInfo
- Publication number
- JP5945532B2 JP5945532B2 JP2013505486A JP2013505486A JP5945532B2 JP 5945532 B2 JP5945532 B2 JP 5945532B2 JP 2013505486 A JP2013505486 A JP 2013505486A JP 2013505486 A JP2013505486 A JP 2013505486A JP 5945532 B2 JP5945532 B2 JP 5945532B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- mmol
- compound
- inhibitor
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(Bc(cc1)cc2c1nc(*)[n]2)(C)C Chemical compound CC(Bc(cc1)cc2c1nc(*)[n]2)(C)C 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32640110P | 2010-04-21 | 2010-04-21 | |
| US61/326,401 | 2010-04-21 | ||
| PCT/EP2011/056396 WO2011131748A2 (en) | 2010-04-21 | 2011-04-21 | Novel inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013525334A JP2013525334A (ja) | 2013-06-20 |
| JP2013525334A5 JP2013525334A5 (enExample) | 2014-06-05 |
| JP5945532B2 true JP5945532B2 (ja) | 2016-07-05 |
Family
ID=44247842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013505486A Active JP5945532B2 (ja) | 2010-04-21 | 2011-04-21 | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8541596B2 (enExample) |
| EP (1) | EP2560953B1 (enExample) |
| JP (1) | JP5945532B2 (enExample) |
| WO (1) | WO2011131748A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103992310B (zh) * | 2013-05-14 | 2016-07-06 | 中国医学科学院医药生物技术研究所 | 一组取代苯并杂环胺衍生物及其制备方法和作为impdh抑制剂的相关应用 |
| US20170363645A1 (en) | 2014-12-19 | 2017-12-21 | Probiodrug Ag | Novel Method for the Detection of pGlu-Abeta Peptides |
| GB201705263D0 (en) | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| EP3521308B1 (en) | 2018-01-31 | 2024-03-13 | Vivoryon Therapeutics N.V. | Humanized and de-immunized antibodies |
| CN115572285B (zh) * | 2021-06-21 | 2024-10-29 | 武汉睿健医药科技有限公司 | Oct4高选择性活化剂 |
| US20250346562A1 (en) * | 2021-06-21 | 2025-11-13 | Iregene Therapeutics Ltd | Oct4 high-selectivity activator |
| CN115572256B (zh) * | 2021-06-21 | 2025-01-24 | 武汉睿健医药科技有限公司 | Oct4高选择性活化剂 |
Family Cites Families (559)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5736816A (ja) | 1980-08-14 | 1982-02-27 | Toshiba Corp | Chodendokoirunoseizohoho |
| JPS57192573A (en) | 1981-05-25 | 1982-11-26 | Hochiki Co | Fire fighting agent |
| JPS60165712A (ja) | 1984-02-08 | 1985-08-28 | パイオニア株式会社 | 可変調整部品の自動調整方法 |
| JPS6126111A (ja) | 1984-07-16 | 1986-02-05 | Shin Meiwa Ind Co Ltd | 産業用ロボツト |
| JPS6137764A (ja) | 1984-07-31 | 1986-02-22 | Suntory Ltd | 抗プロリルエンドペプチダ−ゼ活性を有する新規生理活性化合物 |
| JPS6152021A (ja) | 1984-08-22 | 1986-03-14 | Fujitsu Ltd | スケルチ回路 |
| JPS6172439A (ja) | 1984-09-18 | 1986-04-14 | Sanyo Electric Co Ltd | デ−タ転送方式 |
| JPH0623190B2 (ja) | 1985-04-16 | 1994-03-30 | サントリー株式会社 | インヒビタ−活性を有するｎ−アシルピロリジン誘導体及びその製法並びに用途 |
| US4772587A (en) | 1985-04-16 | 1988-09-20 | Suntory Limited | Dipeptide derivative of fatty acid |
| US4873342A (en) | 1985-04-16 | 1989-10-10 | Suntory Limited | Dipeptide derivative and synthesis and use thereof |
| JPS6224244A (ja) | 1985-07-24 | 1987-02-02 | Konishiroku Photo Ind Co Ltd | ハロゲン化銀写真感光材料 |
| JPS6255644A (ja) * | 1985-09-04 | 1987-03-11 | Konishiroku Photo Ind Co Ltd | ハロゲン化銀写真感光材料 |
| JPS62114957A (ja) | 1985-11-13 | 1987-05-26 | Suntory Ltd | プロリルエンドペプチダ−ゼ阻害作用を有する新規ピロリジン誘導体およびその製法並びに用途 |
| JPH0714878B2 (ja) | 1985-11-14 | 1995-02-22 | サントリー株式会社 | ピロリジンアミドを有効成分とするプロリルエンドペプチダーゼ阻害剤 |
| JPH0764834B2 (ja) | 1985-11-29 | 1995-07-12 | サントリー株式会社 | プロリルエンドペプチダーゼ阻害活性を有する新規ピロリジンアミド誘導体およびその製法並びに用途 |
| CA1320734C (en) | 1986-02-04 | 1993-07-27 | Suntory Limited | Pyrrolidineamide derivative of acylamino acid and pharmaceutical composition containing the same |
| US5198458A (en) | 1986-02-04 | 1993-03-30 | Suntory Limited | Pyrrolidineamide derivatives of acylamino acid and pharmaceutical composition containing the same |
| CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
| JPS6386485A (ja) | 1986-09-30 | 1988-04-16 | Agency Of Ind Science & Technol | トンネル型ジヨセフソン接合素子 |
| SE8604566D0 (sv) * | 1986-10-27 | 1986-10-27 | Haessle Ab | Novel compunds |
| US5223482A (en) | 1986-11-17 | 1993-06-29 | Scios Nova Inc. | Recombinant Alzheimer's protease inhibitory amyloid protein and method of use |
| JPH08806B2 (ja) | 1986-11-18 | 1996-01-10 | サントリー株式会社 | プロリルエンドペプチダ−ゼ阻害作用を有する新規ピロリジンアミド誘導体 |
| EP0268190B1 (en) | 1986-11-20 | 1993-06-16 | Ono Pharmaceutical Co., Ltd. | Prolinal derivatives |
| US5254550A (en) | 1986-11-20 | 1993-10-19 | Ono Pharmaceutical Co., Ltd. | Prolinal derivatives and pharmaceutical compositions thereof |
| JPS63162672A (ja) | 1986-12-25 | 1988-07-06 | Ono Pharmaceut Co Ltd | 新規なプロリナ−ル誘導体、それらの製造方法およびそれらを含有する抗健忘症剤 |
| US5262431A (en) | 1986-12-29 | 1993-11-16 | Ono Pharmaceutical Co., Ltd. | Prolinal derivatives and pharmaceutical compositions thereof |
| DE3783754T2 (de) | 1986-12-29 | 1993-08-05 | Ono Pharmaceutical Co | Prolin-derivate. |
| JPH089591B2 (ja) | 1986-12-29 | 1996-01-31 | 小野薬品工業株式会社 | 新規なプロリナール誘導体 |
| DE3879522T2 (de) | 1987-02-04 | 1993-09-02 | Ono Pharmaceutical Co | Prolinalderivate. |
| EP0461677B1 (en) | 1987-02-23 | 1997-04-16 | Ono Pharmaceutical Co., Ltd. | Novel thiazolidine derivatives |
| JPH07110867B2 (ja) * | 1987-04-04 | 1995-11-29 | 株式会社トクヤマ | ハロゲン化複素環式化合物の製造方法 |
| JPS6442465A (en) | 1987-08-07 | 1989-02-14 | Wakunaga Pharma Co Ltd | N-acylprolylpyrrolidine derivative, production and use thereof |
| JP2649237B2 (ja) | 1988-03-07 | 1997-09-03 | キッセイ薬品工業 株式会社 | チアゾリジン誘導体 |
| US4857524A (en) | 1987-08-08 | 1989-08-15 | Kissei Pharmaceutical Co., Ltd. | Thiazolidine compounds and therapeutic method |
| JP2515558B2 (ja) | 1987-09-10 | 1996-07-10 | 株式会社ヤクルト本社 | 新規なペプチドおよびそれを有効成分とする抗健忘症剤 |
| CA1339014C (en) | 1987-10-08 | 1997-03-25 | Ronald E. Majocha | Antibodies to a4 amyloid peptide |
| JPH0742309B2 (ja) | 1987-11-30 | 1995-05-10 | キッセイ薬品工業株式会社 | チアゾリジン誘導体 |
| JPH01250370A (ja) | 1987-12-23 | 1989-10-05 | Zeria Pharmaceut Co Ltd | 新規アミノ酸イミド誘導体、製法ならびに用途 |
| US5053414A (en) | 1988-04-08 | 1991-10-01 | Ono Pharmaceutical Co., Ltd. | Heterocyclic compounds |
| US5328899A (en) | 1988-07-15 | 1994-07-12 | The Salk Institute For Biological Studies | NPY peptide analogs |
| ZA896374B (en) | 1988-08-26 | 1990-05-30 | Merrell Dow Pharma | Neuropeptide y antagonists |
| ZA896376B (en) | 1988-08-26 | 1990-05-30 | Merrell Dow Pharma | Neuropeptide y agonists |
| JP2531989B2 (ja) | 1988-09-14 | 1996-09-04 | 吉富製薬株式会社 | ピリジン化合物 |
| CA2004028C (en) | 1988-12-08 | 1998-09-22 | Motoki Torizuka | Condensed benzene derivative |
| JPH02207070A (ja) | 1989-02-07 | 1990-08-16 | Zeria Pharmaceut Co Ltd | アミノ酸イミド誘導体、それを含有する医薬及び該化合物の製造中間体 |
| WO1990012005A1 (fr) | 1989-04-13 | 1990-10-18 | Japan Tobacco Inc. | Nouveaux derives aminoacides possedant une activite d'inhibiteur de la prolylendopeptidase |
| AU5525090A (en) | 1989-04-14 | 1990-11-16 | Research Foundation For Mental Hygiene, Inc. | Monoclonal antibody to amyloid peptide |
| WO1990012871A1 (en) | 1989-04-14 | 1990-11-01 | Research Foundation For Mental Hygiene, Inc. | Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10 |
| DK0403159T3 (da) | 1989-06-14 | 2000-08-14 | Smithkline Beecham Corp | Imidazolylalkensyrer |
| DE3939797A1 (de) | 1989-12-01 | 1991-06-06 | Basf Ag | Neue vom neuropeptid y abgeleitete peptide |
| US4985560A (en) | 1990-01-12 | 1991-01-15 | American Home Products Corporation | Pyridazino(4,5-b)indolizines |
| DE122010000024I1 (de) | 1990-02-19 | 2010-07-08 | Novartis Ag | Acylverbindungen |
| JPH04211648A (ja) | 1990-07-27 | 1992-08-03 | Nippon Kayaku Co Ltd | ケト酸アミド誘導体 |
| JPH03255080A (ja) | 1990-03-05 | 1991-11-13 | Yoshitomi Pharmaceut Ind Ltd | ベンゼン化合物 |
| PT97078B (pt) | 1990-03-20 | 1997-07-31 | Sanofi Sa | Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem |
| US4999349A (en) | 1990-03-22 | 1991-03-12 | Bristol-Myers Squibb Co. | BU-4164E - A and B, prolyl endopeptidase inhibitors |
| US5073549A (en) | 1990-03-22 | 1991-12-17 | Bristol-Myers Squibb Company | BU-4164E - A and B, prolyl endopeptidase inhibitors and their methods of use |
| US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
| WO1991018891A1 (en) | 1990-06-04 | 1991-12-12 | Pfizer Inc. | Aromatic pyrrolidine and thiazolidine amides |
| CA2084204A1 (en) | 1990-06-07 | 1991-12-08 | Akihiro Okubo | Arylalkanoylamine derivative and drug containing the same |
| US5506256A (en) | 1990-07-27 | 1996-04-09 | Yoshitomi Pharmaceutical Industries, Ltd. | Proline derivatives possessing prolyl endopeptidase-inhibitory activity |
| JPH05186498A (ja) | 1991-12-27 | 1993-07-27 | Japan Tobacco Inc | プロリン誘導体 |
| EP0468469A2 (en) | 1990-07-27 | 1992-01-29 | Japan Tobacco Inc. | Proline derivatives |
| JPH04235162A (ja) | 1990-08-09 | 1992-08-24 | Zeria Pharmaceut Co Ltd | 新規コハク酸アミド誘導体およびそれを含有する医薬 |
| JPH04208299A (ja) | 1990-11-30 | 1992-07-29 | Ajinomoto Co Inc | プロリルエンドペプチターゼ阻害ペプチド |
| CA2229000C (en) | 1991-02-21 | 2002-04-09 | Sankyo Company, Limited | 1-biphenylimidazole derivatives, their preparation and their therapeutic use |
| US5104880A (en) | 1991-05-01 | 1992-04-14 | Mayo Foundation For Medical Education And Research | Huperzine a analogs as acetylcholinesterase inhibitors |
| WO1992021333A2 (en) | 1991-05-24 | 1992-12-10 | Pharmavene, Inc. | Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors |
| DE69222142T2 (de) | 1991-06-20 | 1998-04-09 | Snow Brand Milk Products Co., Ltd., Sapporo, Hokkaido | Neuartige prolyl-endopeptidase-inhibitoren sna-115 und sna-115t, ihre herstellung, und hierbei verwendete stämme |
| DE4121975A1 (de) | 1991-07-03 | 1993-01-07 | Basf Ag | Thermoplastische formmassen auf der basis von polycarbonaten, styrol/acrylnitril-polymerisaten und polyolefinen |
| CA2113115A1 (en) | 1991-07-29 | 1993-02-18 | Vlad E. Gregor | Quinazoline derivatives as acetylcholinesterase inhibitors |
| TW226375B (enExample) | 1991-10-24 | 1994-07-11 | American Home Prod | |
| CA2126212A1 (en) | 1991-12-19 | 1993-07-08 | Albert Tseng | A novel molecule which inhibits neuropeptide tyrosine biological function |
| JPH05301826A (ja) | 1991-12-24 | 1993-11-16 | Snow Brand Milk Prod Co Ltd | プロリルエンドペプチダーゼ阻害剤 |
| JPH05201970A (ja) | 1992-01-24 | 1993-08-10 | Japan Tobacco Inc | 新規プロリン誘導体 |
| JP3318622B2 (ja) | 1992-05-27 | 2002-08-26 | 独立行政法人産業技術総合研究所 | プロリルエンドペプチダーゼ阻害剤 |
| GB9212308D0 (en) | 1992-06-10 | 1992-07-22 | Ici Plc | Therapeutic compositions |
| GB9213215D0 (en) | 1992-06-20 | 1992-08-05 | Wellcome Found | Peptides |
| JPH06116284A (ja) | 1992-10-02 | 1994-04-26 | Yamanouchi Pharmaceut Co Ltd | 新規ペプチド |
| WO1994007890A1 (fr) | 1992-10-05 | 1994-04-14 | Ube Industries, Ltd. | Compose pyrimidine |
| US5260286A (en) | 1992-10-16 | 1993-11-09 | Japan Tobacco, Inc. | 2-piperidinecarboxylic acid derivatives useful as NMDA receptor antagonists |
| US5536737A (en) | 1992-11-20 | 1996-07-16 | Japan Tobacco Inc. | Compound having prolyl endopeptidase inhibitory activity and pharmaceutical use thereof |
| US5354758A (en) | 1992-12-16 | 1994-10-11 | Japan Tobacco Inc. | Benzomorphans useful as NMDA receptor antagonists |
| JPH06192298A (ja) | 1992-12-24 | 1994-07-12 | Mitsui Toatsu Chem Inc | 新規機能性ペプチド |
| DE4326465A1 (de) | 1993-01-20 | 1995-02-09 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| EP0683234B2 (en) | 1993-01-25 | 2007-06-06 | Takeda Chemical Industries, Ltd. | Antibody against beta-amyloid or their derivative and use thereof |
| JPH06234693A (ja) | 1993-02-09 | 1994-08-23 | Snow Brand Milk Prod Co Ltd | 新規イソテトラセノン系物質及びその製造法 |
| FR2701480B1 (fr) | 1993-02-15 | 1995-05-24 | Sanofi Elf | Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant. |
| EP0611769A1 (en) | 1993-02-16 | 1994-08-24 | Merrell Dow Pharmaceuticals Inc. | Silylated acetylcholinesterase inhibitors |
| AU4982293A (en) | 1993-03-02 | 1994-09-26 | Fujisawa Pharmaceutical Co., Ltd. | Novel heterocyclic compound |
| FR2702150B1 (fr) | 1993-03-03 | 1995-04-07 | Rhone Poulenc Rorer Sa | Application de dérivés de 2H-1,2-4-benzothiadiazine-3(4H)-one-1,1-dioxyde comme antagonistes non compétitifs du récepteur NMDA. |
| FR2703050B1 (fr) | 1993-03-24 | 1995-04-28 | Adir | Nouveaux dérivés bicycliques azotés, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| EP0627400A1 (en) | 1993-06-04 | 1994-12-07 | Merrell Dow Pharmaceuticals Inc. | Aromatic acetylcholinesterase inhibitors |
| JPH11501281A (ja) | 1993-06-18 | 1999-02-02 | ユニバーシティ オブ シンシナティ | 神経ペプチドｙアンタゴニスト及びアゴニスト |
| AU6983894A (en) | 1993-06-30 | 1995-01-24 | Zeria Pharmaceutical Co., Ltd. | Thiazolidine derivative and medicine containing the same |
| FR2707645B1 (fr) | 1993-07-16 | 1995-08-11 | Rhone Poulenc Rorer Sa | Dérivés d'imidazo[1,2-a]pirazine-4-one, leur préparation et les médicaments les contenant. |
| FR2707643B1 (fr) | 1993-07-16 | 1995-08-11 | Rhone Poulenc Rorer Sa | Dérivés d'imidazo[1,2-a]pyrazine-4-one, leur préparation et les médicaments les contenant. |
| EP0709373B1 (en) | 1993-07-23 | 2001-10-17 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Pyrrolidine derivative |
| AU7275894A (en) * | 1993-08-04 | 1995-02-28 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazolylalkylamine derivative and pharmaceutical composition thereof |
| FR2711993B1 (fr) | 1993-11-05 | 1995-12-01 | Rhone Poulenc Rorer Sa | Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation. |
| DK0731788T3 (da) | 1993-12-02 | 2003-01-20 | Merrell Pharma Inc | Prolylendopeptidaseinhibitorer |
| IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| FR2717805B1 (fr) | 1994-03-28 | 1996-05-10 | Rhone Poulenc Rorer Sa | Dérivés de 5H-indeno[1,2-b]pyrazine-2,3-dione, leur préparation et les médicaments les contenant . |
| FR2717812B1 (fr) | 1994-03-28 | 1996-05-10 | Rhone Poulenc Rorer Sa | Indeno[1,2-e]pyrazine-4-ones, leur préparation et les médicaments les contenant. |
| FR2717811B1 (fr) | 1994-03-28 | 1996-04-26 | Rhone Poulenc Rorer Sa | Dérivés d'imidazo[1,2-a]pyrazine-4-one, leur préparation et les médicaments les contenant. |
| FR2717813B1 (fr) | 1994-03-28 | 1996-05-10 | Rhone Poulenc Rorer Sa | Dérivés d'imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one, leur préparation et les médicaments les contenant . |
| JPH07267988A (ja) | 1994-03-31 | 1995-10-17 | Yamanouchi Pharmaceut Co Ltd | 新規ペプチド |
| GB9410320D0 (en) | 1994-05-24 | 1994-07-13 | Fisons Corp | Novel therapeutic method |
| GB9418443D0 (en) | 1994-09-13 | 1994-11-02 | Pfizer Ltd | Therapeutic agents |
| EP0716854A3 (en) | 1994-10-20 | 1996-08-28 | Lilly Co Eli | Compositions for inhibiting neuropeptide Y |
| US6562862B1 (en) | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
| US5663192A (en) | 1994-10-20 | 1997-09-02 | Eli Lilly And Company | Heterocyclic neuropeptide Y receptor antagonists |
| FR2726275B1 (fr) | 1994-11-02 | 1996-12-06 | Rhone Poulenc Rorer Sa | Spiro heterocycle-imidazo(1,2-a)indeno(1,2-e)pyrazine)-4'- ones, leur preparation et les medicaments les contenants |
| IL116584A0 (en) | 1994-12-29 | 1996-03-31 | Res Dev Foundation | Novel flavin adenine dinucleotide analogue inhibitors of monoamine oxidase |
| US5691368A (en) | 1995-01-11 | 1997-11-25 | Hoechst Marion Roussel, Inc. | Substituted oxazolidine calpain and/or cathepsin B inhibitors |
| GB9500601D0 (en) | 1995-01-12 | 1995-03-01 | Wellcome Found | Modified peptides |
| US5786180A (en) | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
| US5552411A (en) | 1995-05-26 | 1996-09-03 | Warner-Lambert Company | Sulfonylquinolines as central nervous system and cardiovascular agents |
| US5668151A (en) | 1995-06-07 | 1997-09-16 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: piperidine derivatives |
| IL117997A0 (en) | 1995-06-07 | 1996-10-31 | Pfizer | Neuropeptide Y1 specific ligands |
| US5635503A (en) | 1995-06-07 | 1997-06-03 | Bristol-Myers Squibb Company | Dihydropyridine npy antagonists: piperazine derivatives |
| US5554621A (en) | 1995-06-07 | 1996-09-10 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: nitrogen heterocyclic derivatives |
| JP3727383B2 (ja) | 1995-07-31 | 2005-12-14 | 月桂冠株式会社 | プロリルエンドペプチダーゼ阻害剤 |
| AU717422B2 (en) | 1995-09-01 | 2000-03-23 | Eli Lilly And Company | Indolyl neuropeptide Y receptor antagonists |
| WO1997012613A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| ES2100129B1 (es) | 1995-10-11 | 1998-02-16 | Medichem Sa | Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion. |
| DE19544687A1 (de) | 1995-11-30 | 1997-06-05 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE19544686A1 (de) | 1995-11-30 | 1997-06-05 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE19544685A1 (de) | 1995-11-30 | 1997-06-05 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| WO1997020823A2 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | 2-amino quinazoline derivatives as npy receptor antagonists |
| WO1997019682A1 (en) | 1995-12-01 | 1997-06-05 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
| AU7692896A (en) | 1995-12-01 | 1997-06-27 | Novartis Ag | Quinazolin-2,4-diazirines as NPY receptor antagonist |
| AU7626496A (en) | 1995-12-01 | 1997-06-27 | Ciba-Geigy Ag | Heteroaryl compounds |
| WO1997020821A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl derivatives |
| JPH09157253A (ja) | 1995-12-12 | 1997-06-17 | Yamanouchi Pharmaceut Co Ltd | 新規アミノ酸誘導体 |
| ZA9610741B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| ZA9610745B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| ZA9610736B (en) | 1995-12-22 | 1997-06-27 | Warner Lambert Co | 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists |
| EP0871442A1 (en) | 1996-01-09 | 1998-10-21 | Eli Lilly And Company | Benzimidzolyl neuropeptide y receptor antagonists |
| GB9605027D0 (en) | 1996-03-09 | 1996-05-08 | Pfizer Ltd | Quinoxalinediones |
| US5662723A (en) | 1996-03-22 | 1997-09-02 | Libbey Glass Inc. | Apparatus and method for forming a decorative pattern on glassware having an edge |
| EP0892796B1 (en) | 1996-04-12 | 2001-10-24 | Aventis Pharmaceuticals Inc. | Isatin derivatives as acetylcholinesterase inhibitors and analgesics |
| DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| EP1007073A4 (en) | 1996-06-04 | 2002-03-27 | Synaptic Pharma Corp | METHODS OF MODIFYING FOOD BEHAVIOR, COMPOUNDS USEFUL IN SAID METHODS, AND DNA ENCODING A HYPOTHALAMIC NEUROPEPTIDE Y / PEPTIDE YY Y5 RECEPTOR |
| DE69715899T2 (de) | 1996-07-05 | 2003-05-28 | The Wwk Trust, Kent | Zusammensetzungen zur behandlung der peripheren neuropathie, die antidepressiven verbindungen und/oder monoamino-oxidaseinhibitoren und/oder vitamin b12 und/oder neurotransmitter-vorläufer oder induktoren enthalten |
| EP0918761B1 (en) | 1996-07-23 | 2003-05-02 | Neurogen Corporation | Certain amido- and amino-substituted benzylamine derivatives; a new class of neuropeptite y1 specific ligands |
| EP0915859B1 (en) | 1996-07-23 | 2003-01-02 | Neurogen Corporation | Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands |
| US5985873A (en) | 1996-07-23 | 1999-11-16 | Neurogen Corporation | Certain substituted benzylamine derivatives a new class of Neuropeptide-Y1 specific ligands |
| WO1998005337A1 (en) | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| EP0927167A1 (en) | 1996-08-14 | 1999-07-07 | Warner-Lambert Company | 2-phenyl benzimidazole derivatives as mcp-1 antagonists |
| ES2176776T3 (es) | 1996-08-23 | 2002-12-01 | Agouron Pharma | Ligandos del neuropeptido-y. |
| JP3880664B2 (ja) | 1996-09-04 | 2007-02-14 | 月桂冠株式会社 | プロリルエンドペプチダーゼ阻害ペプチド |
| WO1998010757A2 (en) | 1996-09-11 | 1998-03-19 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicity |
| WO1998015647A1 (en) | 1996-10-08 | 1998-04-16 | Novartis Ag | Modulation of apoptosis |
| FR2754709B1 (fr) | 1996-10-23 | 1999-03-05 | Sanofi Sa | Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| US6011155A (en) | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| AU5716898A (en) | 1997-01-08 | 1998-08-03 | Warner-Lambert Company | Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease |
| US20030068316A1 (en) | 1997-02-05 | 2003-04-10 | Klein William L. | Anti-ADDL antibodies and uses thereof |
| JP2894445B2 (ja) | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Ｃｅｔｐ活性阻害剤として有効な化合物 |
| AU6417198A (en) | 1997-03-13 | 1998-09-29 | Bioresearch Ireland a division of Eolas - The Irish Science and Technology Agency | Cytoprotective agents comprising monoamine oxidase inhibitors |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| WO1998044955A1 (en) | 1997-04-09 | 1998-10-15 | Mindset Ltd. | Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof |
| EP0975584B1 (en) | 1997-04-16 | 2002-09-25 | Arqule, Inc. | Synthesis and use of alpha-ketoamide derivatives and arrays |
| JP2001527554A (ja) | 1997-05-07 | 2001-12-25 | アルゴス ファーマシューティカル コーポレーション | 抗うつ薬とｎｍｄａレセプター拮抗薬とを組み合わせる神経障害痛の治療用組成物及び治療方法 |
| WO1998050075A1 (en) | 1997-05-07 | 1998-11-12 | Algos Pharmaceutical Corporation | Cox-2 inhibitors in combination with nmda-blockers for treating pain |
| UA61962C2 (uk) | 1997-06-30 | 2003-12-15 | Мерц Фарма Гмбх Унд Ко. Кгаа | Сполука 1-аміноалкілциклогексану, фармацевтична композиція на її основі та спосіб лікування |
| GB9716657D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| GB9716879D0 (en) | 1997-08-08 | 1997-10-15 | Shire Int Licensing Bv | Treatment of attention deficit disorders |
| WO1999007413A1 (en) | 1997-08-11 | 1999-02-18 | Algos Pharmaceutical Corporation | Substance p inhibitors in combination with nmda-blockers for treating pain |
| SE9703376D0 (sv) | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
| SE9703414D0 (sv) | 1997-09-23 | 1997-09-23 | Astra Ab | New compounds |
| US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| EP2823812A1 (en) | 1998-02-02 | 2015-01-14 | Trustees Of Tufts College | Dipeptidylpeptidase IV inhibitors for use in the treatment of Type II diabetes |
| EP1062222A1 (en) | 1998-03-09 | 2000-12-27 | Fondatech Benelux N.V. | Serine peptidase modulators |
| US6007841A (en) | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
| GB9805561D0 (en) | 1998-03-16 | 1998-05-13 | Merck Sharp & Dohme | A combination of therapeutic agents |
| US6541208B1 (en) | 1998-03-17 | 2003-04-01 | University Of Maryland Biotechnology Institute | Diagnostic method for distinguishing HIV-associated dementia from other forms of dementia |
| DE19812331A1 (de) | 1998-03-20 | 1999-09-23 | Merck Patent Gmbh | Piperidinderivate |
| US6054451A (en) | 1998-04-21 | 2000-04-25 | Algos Pharmaceutical Corporation | Analgesic composition and method for alleviating pain |
| WO1999057119A1 (en) | 1998-05-04 | 1999-11-11 | Neotherapeutics, Inc. | Novel dopamine-like 9-substituted hypoxanthine and methods of use |
| AU3786299A (en) | 1998-05-04 | 1999-11-23 | Neotherapeutics, Inc. | Novel serotonin-like 9-substituted hypoxanthine and methods of use |
| MXPA00011348A (es) | 1998-05-21 | 2003-04-22 | Univ Tennesse Res Corp | Metodos para la remocion de material amiloide utilizando anticuerpos anti-amiloide. |
| DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
| DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
| DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
| PE20000728A1 (es) | 1998-06-26 | 2000-08-21 | Cocensys Inc | Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda |
| US6262081B1 (en) | 1998-07-10 | 2001-07-17 | Dupont Pharmaceuticals Company | Composition for and method of treating neurological disorders |
| DE19834591A1 (de) | 1998-07-31 | 2000-02-03 | Probiodrug Ges Fuer Arzneim | Verfahren zur Steigerung des Blutglukosespiegels in Säugern |
| US6218383B1 (en) | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
| IL125809A (en) | 1998-08-17 | 2005-08-31 | Finetech Lab Ltd | Process and intermediates for production of donepezil and related compounds |
| IT1304904B1 (it) | 1998-09-11 | 2001-04-05 | Eisai Co Ltd | Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche |
| IL142588A0 (en) | 1998-10-16 | 2002-03-10 | Janssen Pharmaceutica Nv | Therapy for improving cognition |
| CA2351224A1 (en) | 1998-11-12 | 2000-05-25 | Algos Pharmaceutical Corporation | Cox-2 inhibitors in combination with nmda-blockers for treating pain |
| AU1738800A (en) | 1998-11-23 | 2000-06-13 | Bonnie Davis | Dosage formulations for acetylcholinesterase inhibitors |
| WO2000030674A1 (en) | 1998-11-26 | 2000-06-02 | Ferring Bv | Neuropeptide y y4 agents in the treatment of reproductive disorders |
| ATE306264T1 (de) | 1998-12-11 | 2005-10-15 | Bonnie M Davis | Verwendung von acetylcholinesterase inhibitoren zur modulierung der hypothalamus-hypophysen- gonadenachse |
| IL144214A0 (en) | 1999-01-13 | 2002-05-23 | Warner Lambert Co | Benzoheterocycles and their use as mek inhibitors |
| GB9902455D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902453D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902459D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902461D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902452D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| EP1163220A1 (en) | 1999-03-23 | 2001-12-19 | Sumitomo Pharmaceuticals Company, Limited | Tricyclic indole-2-carboxylic acid compound used as nmda receptor antagonist |
| WO2000063250A1 (en) | 1999-04-15 | 2000-10-26 | Merck Frosst Canada & Co. | Antibodies that recognize app cleaved by caspases and methods of use |
| US6121311A (en) | 1999-04-28 | 2000-09-19 | Japan Tobacco Inc. | Method for treating cocainism |
| HK1041263A1 (zh) | 1999-05-05 | 2002-07-05 | Ortho-Mcneil Pharmaceutical, Inc. | 可用於治疗肥胖和其他疾病的3a，4，5，9b-四氢-1h-苯并[e]吲-2-基胺衍生的神经肽y受体配体 |
| JP3148739B2 (ja) | 1999-05-19 | 2001-03-26 | ドーマー株式会社 | プロリルエンドペプチダーゼ阻害剤 |
| ES2312348T3 (es) | 1999-06-16 | 2009-03-01 | Boston Biomedical Research Institute | Control inmunologico de niveles de beta-amiloide in vivo. |
| US6172081B1 (en) | 1999-06-24 | 2001-01-09 | Novartis Ag | Tetrahydroisoquinoline 3-carboxamide derivatives |
| US6107317A (en) | 1999-06-24 | 2000-08-22 | Novartis Ag | N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US6110949A (en) | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US6524616B1 (en) | 1999-06-25 | 2003-02-25 | Wake Forest University Health Services | Compositions and methods for treating or preventing neurodegeneration and cognitive decline and dysfunction associated with alzheimer's disease, aging, other dementia related disorders and estrogen deficiency related conditions |
| US6316449B1 (en) | 1999-07-08 | 2001-11-13 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists |
| CZ2002233A3 (cs) * | 1999-07-21 | 2002-04-17 | Fujisawa Pharmaceutical Co., Ltd. | Benzimidazolonové deriváty, způsob jejich výroby a farmaceutický prostředek |
| DE19936719A1 (de) | 1999-08-06 | 2001-02-15 | Gruenenthal Gmbh | Substituierte 1,5-Dihydropyrrol-2-on-Derivate |
| DE19936521A1 (de) | 1999-08-06 | 2001-02-15 | Gruenenthal Gmbh | Substituierte Pyrrolidin-2,3,4-trion-3-oxim-Derivate |
| EP1307219A4 (en) | 1999-08-13 | 2005-04-06 | Univ Columbia | METHODS OF INHIBITING BETA FIBRILLE BINDING BETA TO RAGE RECEPTOR, AND CONSEQUENCES THEREOF |
| EP1078632A1 (en) | 1999-08-16 | 2001-02-28 | Sanofi-Synthelabo | Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity |
| DE19940130A1 (de) | 1999-08-24 | 2001-03-01 | Probiodrug Ges Fuer Arzneim | Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung |
| TWI283577B (en) | 1999-10-11 | 2007-07-11 | Sod Conseils Rech Applic | Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof |
| UA72558C2 (uk) | 1999-11-01 | 2005-03-15 | Мерц Фарма Гмбх Унд Ко. Кгаа | 1-аміноалкілциклогексанові антагоністи рецептора nmda |
| AU1916401A (en) | 1999-11-12 | 2001-06-06 | Guilford Pharmaceuticals Inc. | Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
| GB9928330D0 (en) | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
| WO2001053255A1 (en) | 2000-01-24 | 2001-07-26 | Merck Sharp & Dohme Limited | Gamma-secretase inhibitors |
| AU2001228309A1 (en) | 2000-01-24 | 2001-08-07 | Novo-Nordisk A/S | N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv |
| DE60130538T2 (de) | 2000-02-03 | 2008-06-12 | Millenium Pharmaceuticals, Inc., Cambridge | Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung |
| IL151378A0 (en) | 2000-02-24 | 2003-04-10 | Univ Washington | Humanized antibodies that sequester amyloid beta peptide |
| GB0005251D0 (en) | 2000-03-03 | 2000-04-26 | Merck Sharp & Dohme | Therapeutic compounds |
| US20030144255A1 (en) | 2000-03-06 | 2003-07-31 | Bain Allen I | Compositions for prevention and treatment of dementia |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| US6992081B2 (en) | 2000-03-23 | 2006-01-31 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
| JP2003528071A (ja) | 2000-03-23 | 2003-09-24 | エラン ファーマスーティカルズ インコーポレイテッド | アルツハイマー病治療用組成物および方法 |
| GB0008710D0 (en) | 2000-04-07 | 2000-05-31 | Merck Sharp & Dohme | Therapeutic compounds |
| US6706741B2 (en) | 2000-04-13 | 2004-03-16 | Eisai Co., Ltd. | Acetylcholinesterase inhibitors containing 1-benzyl-pyridinium salts |
| AU2001255620A1 (en) | 2000-04-26 | 2001-11-07 | Warner-Lambert Company | Cyclohexylamine derivative as subtype selective NMDA receptor antagonists |
| GB0010183D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
| GB0010188D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
| US20010036949A1 (en) | 2000-05-09 | 2001-11-01 | Coe Jotham Wadsworth | Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal |
| AU2001261487A1 (en) | 2000-06-01 | 2001-12-11 | Warner Lambert Company | Cyclohexylamine derivatives as subtype selective nmda receptor antagonists |
| BR0111267A (pt) | 2000-06-06 | 2003-12-16 | Warner Lambert Co | Cicloexilaminas bicìclicas e seu uso como antagonistas do receptor de nmda |
| JP2004501145A (ja) | 2000-06-22 | 2004-01-15 | ファーモス コーポレイション | 向精神作用をもたない新規なカンナビノイド |
| GB0015488D0 (en) | 2000-06-23 | 2000-08-16 | Merck Sharp & Dohme | Therapeutic agents |
| US6713276B2 (en) | 2000-06-28 | 2004-03-30 | Scios, Inc. | Modulation of Aβ levels by β-secretase BACE2 |
| US6686449B2 (en) | 2000-06-30 | 2004-02-03 | Pharmacia & Upjohn Company | Mutant presenilin 1 polypeptides |
| JP2004502665A (ja) | 2000-06-30 | 2004-01-29 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病を治療する化合物 |
| AU6895801A (en) | 2000-07-04 | 2002-01-14 | Novo Nordisk As | Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv |
| GB0016681D0 (en) | 2000-07-06 | 2000-08-23 | Merck Sharp & Dohme | Therapeutic compounds |
| US6556971B1 (en) | 2000-09-01 | 2003-04-29 | Snap-On Technologies, Inc. | Computer-implemented speech recognition system training |
| US20040236450A1 (en) | 2000-09-25 | 2004-11-25 | Motorwiz, Inc. | Model-based machine diagnostics and prognostics using theory of noise and communications |
| US20020151591A1 (en) | 2000-10-17 | 2002-10-17 | Anabella Villalobos | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders |
| HU227197B1 (en) | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| ES2248397T3 (es) | 2000-11-02 | 2006-03-16 | MERCK SHARP & DOHME LTD. | Sulfamidas como inhibidores de la gamma-secretasa. |
| US20020150948A1 (en) | 2000-11-03 | 2002-10-17 | Gerardo Castillo | Antibody PTI-HS7 for treatment of alzheimer's disease and other amyloidoses and parkinson's disease |
| TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US6495335B2 (en) | 2000-12-07 | 2002-12-17 | Mario Chojkier | Compositions and methods for diagnosing alzheimer's disease |
| US6670364B2 (en) | 2001-01-31 | 2003-12-30 | Telik, Inc. | Antagonists of MCP-1 function and methods of use thereof |
| TWI245761B (en) | 2001-03-01 | 2005-12-21 | Telik Inc | Antagonists of MCP-1 function and methods of use thereof |
| WO2002072542A2 (en) | 2001-03-08 | 2002-09-19 | Emory University | Ph-dependent nmda receptor antagonists |
| US6649196B2 (en) | 2001-03-12 | 2003-11-18 | Mayo Foundation For Medical Education And Research | Methods of reducing β-amyloid polypeptides |
| US6815175B2 (en) | 2001-03-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder |
| US6677365B2 (en) | 2001-04-03 | 2004-01-13 | Telik, Inc. | Antagonists of MCP-1 function and methods of use thereof |
| US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
| ES2318006T3 (es) | 2001-04-30 | 2009-05-01 | Eli Lilly And Company | Anticuerpos humanizados que reconocen el peptido beta-amiloide. |
| ES2312569T3 (es) | 2001-04-30 | 2009-03-01 | Eli Lilly And Company | Anticuerpos humanizados. |
| FR2824825B1 (fr) | 2001-05-15 | 2005-05-06 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| SI20922A (sl) | 2001-05-18 | 2002-12-31 | Krka Tovarna Zdravil, D.D., Novo Mesto | Monoklonsko protitelo, ki nevtralizira aktivnost katepsina B, in njegove uporabe |
| US6562783B2 (en) | 2001-05-30 | 2003-05-13 | Neurologic, Inc. | Phosphinylmethyl and phosphorylmethyl succinic and glutauric acid analogs as β-secretase inhibitors |
| WO2002098849A2 (en) | 2001-06-01 | 2002-12-12 | Elan Pharmaceuticals, Inc. | Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer’s disease and similar diseases |
| EP1406872B1 (en) | 2001-06-20 | 2007-12-19 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| DE60209348T2 (de) | 2001-06-20 | 2006-10-12 | Merck & Co., Inc. | Dipeptidylpeptidase-hemmer zur behandlung von diabetes |
| GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
| ATE370943T1 (de) | 2001-06-27 | 2007-09-15 | Smithkline Beecham Corp | Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren |
| WO2003002122A1 (en) | 2001-06-27 | 2003-01-09 | Elan Pharmaceuticals, Inc. | Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease |
| ATE385238T1 (de) | 2001-06-27 | 2008-02-15 | Probiodrug Ag | Verwendung von dpiv-inhibitoren als therapeutika für krankhafte neurologische zustände |
| DE10154689A1 (de) | 2001-11-09 | 2003-05-22 | Probiodrug Ag | Substituierte Aminoketonverbindungen |
| DE10150203A1 (de) | 2001-10-12 | 2003-04-17 | Probiodrug Ag | Peptidylketone als Inhibitoren der DPIV |
| WO2003002530A2 (en) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
| CN1723196A (zh) | 2001-06-27 | 2006-01-18 | 史密丝克莱恩比彻姆公司 | 作为二肽酶抑制剂的氟代吡咯烷 |
| WO2003002593A2 (en) | 2001-06-27 | 2003-01-09 | Probiodrug Ag | Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis |
| EP1404675B1 (en) | 2001-07-03 | 2008-03-12 | Novo Nordisk A/S | Dpp-iv-inhibiting purine derivatives for the treatment of diabetes |
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| ATE408611T1 (de) | 2001-07-24 | 2008-10-15 | Richter Gedeon Nyrt | Piperidine als nmda-rezeptorantagonisten |
| US20040234990A1 (en) | 2001-07-31 | 2004-11-25 | Hiroto Komano | Method of screening alzheimer's disease-associated gene |
| JP4729717B2 (ja) | 2001-08-03 | 2011-07-20 | 株式会社医学生物学研究所 | ＧＭ１ガングリオシド結合型アミロイドβタンパク質を認識する抗体、及び該抗体をコードするＤＮＡ |
| CN1304390C (zh) | 2001-08-03 | 2007-03-14 | 先灵公司 | 新颖的γ—分泌酶抑制剂 |
| CN1780621A (zh) | 2001-08-03 | 2006-05-31 | 先灵公司 | 作为γ分泌酶抑制剂的磺酰胺衍生物 |
| WO2003015691A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | RAPID IMPROVEMENT OF COGNITION IN CONDITIONS RELATED TO A$g(b) |
| CA2451998A1 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Anti-a.beta. antibodies |
| WO2003020289A1 (en) | 2001-08-30 | 2003-03-13 | Ortho-Mcneil Pharmaceutical, Inc. | Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors |
| EP1426366A4 (en) | 2001-09-14 | 2004-12-08 | Mitsubishi Pharma Corp | THIAZOLIDE DERIVATIVES AND THEIR MEDICAL USE |
| EP1463727A2 (en) | 2001-09-19 | 2004-10-06 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme dpp-iv |
| CA2464736A1 (en) | 2001-10-23 | 2003-05-15 | Oklahoma Medical Research Foundation | Beta-secretase inhibitors and methods of use |
| GB0125445D0 (en) | 2001-10-23 | 2001-12-12 | Ferring Bv | Protease Inhibitors |
| GB0125446D0 (en) | 2001-10-23 | 2001-12-12 | Ferring Bv | Novel anti-diabetic agents |
| US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
| US7304040B2 (en) | 2001-11-02 | 2007-12-04 | Kensuke Egashira | Suppression of post-transplant arteriosclerosis |
| WO2003039467A2 (en) | 2001-11-02 | 2003-05-15 | Diagenics International Corporation | Monoclonal antibodies specific for beta-amyloid. |
| WO2003040183A2 (en) | 2001-11-09 | 2003-05-15 | The Genetics Company, Inc | Compounds for the diagnosis/prevention/treatment of alzheimer's disease |
| JP2005514362A (ja) | 2001-11-19 | 2005-05-19 | イーラン ファーマスーティカルズ、インコーポレイテッド | ３，４二置換、３，５二置換、及び３，４，５置換ピペリジン及びピペラジン |
| CA2466841A1 (en) | 2001-11-21 | 2003-06-05 | New York University | Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid .beta., prion protein, amylin, .alpha.-synuclein, or polyglutamine repeats for induction of an immune response thereto |
| EP2316470A3 (en) | 2001-11-26 | 2011-08-24 | Trustees Of Tufts College | Peptidomimetic inhibitors of post-proline cleaving enzymes |
| AU2002354433A1 (en) | 2001-12-06 | 2003-06-17 | Japan As Represented By Secretary Of Chubu National Hospital | Alzheimer's disease-associated gene and protein and use thereof |
| WO2003051374A2 (en) | 2001-12-17 | 2003-06-26 | New York State Office Of Mental Health | SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES |
| IL162533A0 (en) | 2001-12-19 | 2005-11-20 | Atherogenics Inc | Chalcone derivatives and their use to treat diseases |
| US20060210555A1 (en) | 2001-12-21 | 2006-09-21 | Antigenics, Inc. | Compositions comprising immunoreactive reagents and saponins, and methods of use thereof |
| AU2002360732A1 (en) | 2001-12-26 | 2003-07-24 | Guilford Pharmaceuticals | Change inhibitors of dipeptidyl peptidase iv |
| US6727261B2 (en) | 2001-12-27 | 2004-04-27 | Hoffman-La Roche Inc. | Pyrido[2,1-A]Isoquinoline derivatives |
| WO2003057204A2 (en) | 2002-01-08 | 2003-07-17 | Nordic Bioscience A/S | Modulation of iamt (pimt or pcmt) in immune system |
| JP2005516967A (ja) | 2002-01-18 | 2005-06-09 | ザ ジェネティクス カンパニー インコーポレーティッド | β−セクレターゼインヒビター |
| WO2003063760A2 (en) | 2002-01-31 | 2003-08-07 | Tel Aviv University Future Technology Development L.P. | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases |
| TW200302717A (en) | 2002-02-06 | 2003-08-16 | Schering Corp | Novel gamma secretase inhibitors |
| US20040171614A1 (en) | 2002-02-06 | 2004-09-02 | Schering-Plough Corporation | Novel gamma secretase inhibitors |
| CN1308311C (zh) | 2002-02-13 | 2007-04-04 | 霍夫曼-拉罗奇有限公司 | 新型吡啶－和喹啉－衍生物 |
| ATE472536T1 (de) | 2002-02-13 | 2010-07-15 | Hoffmann La Roche | Pyridin- und pyrimidin-derivate |
| AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| HUP0200849A2 (hu) | 2002-03-06 | 2004-08-30 | Sanofi-Synthelabo | N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| TWI343377B (en) | 2002-03-13 | 2011-06-11 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| EP1490335B1 (en) | 2002-03-25 | 2007-09-19 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| WO2003082820A1 (en) | 2002-03-29 | 2003-10-09 | Eisai Co., Ltd. | (1-indanone)-(1,2,3,6-tetrahydropyridine) derivative |
| US20070134247A9 (en) | 2002-04-12 | 2007-06-14 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
| CN100360555C (zh) | 2002-04-19 | 2008-01-09 | 多伦多大学董事局 | 治疗阿尔茨海默氏病的免疫学方法及组合物 |
| CN1319987C (zh) | 2002-04-24 | 2007-06-06 | 森启 | γ－分泌酶抑制剂 |
| ES2315494T3 (es) | 2002-04-26 | 2009-04-01 | Schering Corporation | Antagonistas muscarinicos. |
| AU2003230392A1 (en) | 2002-05-17 | 2003-12-12 | Merck And Co., Inc. | Beta-secretase inhibitors |
| EP1509232B1 (en) | 2002-05-31 | 2008-11-19 | H. Lundbeck A/S | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
| MXPA04011958A (es) | 2002-06-04 | 2005-03-31 | Pfizer Prod Inc | Amidas ciclicas fluoradas como inhibidores de la dipeptidil peptidasa iv. |
| AU2003233010A1 (en) | 2002-06-04 | 2003-12-19 | Pfizer Products Inc. | Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof |
| US20060100199A1 (en) | 2002-06-06 | 2006-05-11 | Seiji Yoshikawa | Novel condensed imidazole derivatives |
| US20050171300A1 (en) | 2002-06-19 | 2005-08-04 | Luc Moens | Semi-gloss powder coating compositions |
| JPWO2004007446A1 (ja) | 2002-07-10 | 2005-11-10 | アステラス製薬株式会社 | 新規なアゼチジン誘導体又はその塩 |
| JP4530852B2 (ja) | 2002-07-15 | 2010-08-25 | メルク・シャープ・エンド・ドーム・コーポレイション | 糖尿病治療のためのピペリジノピリミジンジペプチジルペプチダーゼ阻害剤 |
| EP1523309A2 (en) | 2002-07-19 | 2005-04-20 | Khalid Iqbal | Nmda receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau |
| US7557137B2 (en) | 2002-08-05 | 2009-07-07 | Bristol-Myers Squibb Company | Gamma-lactams as beta-secretase inhibitors |
| CN102964347B (zh) | 2002-08-21 | 2015-11-18 | 勃林格殷格翰制药两合公司 | 8-[3-氨基-哌啶-1-基]-黄嘌呤化合物，其制备方法及作为药物制剂的用途 |
| DE10238477A1 (de) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| DE10238470A1 (de) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| WO2006039807A1 (en) | 2004-10-15 | 2006-04-20 | Biopharmacopae Design International Inc. | Methods and therapeutic compositions comprising plant extracts for the treatment of cancer |
| ES2201929B1 (es) | 2002-09-12 | 2005-05-16 | Araclon Biotech, S.L. | Anticuerpos policlonales, metodo de preparacion y uso de los mismos. |
| ATE506072T1 (de) | 2002-09-12 | 2011-05-15 | Univ California | Immunogene und entsprechende antikörper, die spezifisch sind für häufige hochmolekulare aggregations-zwischenprodukte von amyloiden aus proteinen unterschiedlicher sequenz |
| CN1681926A (zh) | 2002-09-12 | 2005-10-12 | 财团法人化学及血清疗法研究所 | 人的抗人mcp－1抗体和该抗体的片段 |
| AU2003282800B2 (en) | 2002-09-19 | 2009-10-29 | Abbvie Inc. | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
| AU2003282804A1 (en) | 2002-09-20 | 2004-04-08 | Axys Pharmaceuticals, Inc. | 3-(3,5-disubstituted-4-hydroxyphenyl)propionamide derivatives as cathepsin b inhibitors |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| WO2004029629A1 (en) | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
| EP1545582A4 (en) | 2002-10-01 | 2008-09-17 | Univ Northwestern | DIFFUSIBLE DERIVATIVES DERIVED FROM AMYLOID BETA (ADDL), ADDL SUBSTITUTE, ADDL BINDING MOLECULES, AND USES THEREOF |
| GB0223039D0 (en) | 2002-10-04 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic compounds |
| GB0223038D0 (en) | 2002-10-04 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic compounds |
| ATE370141T1 (de) | 2002-10-07 | 2007-09-15 | Merck & Co Inc | Antidiabetische heterocyclische beta- aminoverbindungen als inhibitoren von dipeptidylpeptidase |
| AU2003269850A1 (en) | 2002-10-08 | 2004-05-04 | Novo Nordisk A/S | Hemisuccinate salts of heterocyclic dpp-iv inhibitors |
| GB0223494D0 (en) | 2002-10-09 | 2002-11-13 | Neuropharma Sa | Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer's disease |
| EP1633786A4 (en) | 2002-10-09 | 2007-07-25 | Rinat Neuroscience Corp | METHOD FOR TREATING ALZHEIMER DISEASE WITH ANTIBODIES TO AMYLOID BETA PEPTIDE AND COMPOSITIONS THEREOF |
| DK1556362T3 (da) | 2002-10-18 | 2008-06-09 | Merck & Co Inc | Heterocykliske beta-aminodipeptidylpeptidaseinhibitorer til behandling eller forebyggelse af diabetes |
| AU2003274353B2 (en) | 2002-10-24 | 2007-04-05 | Merz Pharma Gmbh & Co. Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| US20040082543A1 (en) | 2002-10-29 | 2004-04-29 | Pharmacia Corporation | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain |
| AU2003286776A1 (en) | 2002-10-30 | 2004-06-07 | Guilford Pharmaceuticals Inc. | Novel inhibitors of dipeptidyl peptidase iv |
| AU2003285296A1 (en) | 2002-10-30 | 2004-05-25 | Nordic Bioscience A/S | Coumpounds modulating the activity of gapdh and/or iamt |
| GB0225474D0 (en) | 2002-11-01 | 2002-12-11 | Merck Sharp & Dohme | Therapeutic agents |
| FR2846667B1 (fr) | 2002-11-06 | 2004-12-31 | Pasteur Institut | Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives |
| MXPA05004890A (es) | 2002-11-07 | 2005-07-22 | Merck & Co Inc | Derivados de fenilalanina como inhibidores de dipeptidilpeptidasa para el tratamiento o prevencion de diabetes. |
| EP1562897B1 (en) | 2002-11-12 | 2009-09-16 | Merck & Co., Inc. | Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease |
| AU2002952946A0 (en) | 2002-11-27 | 2002-12-12 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
| AU2003297564A1 (en) | 2002-12-04 | 2004-06-23 | Merck & Co., Inc. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| US7420079B2 (en) | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
| WO2004056727A2 (en) | 2002-12-19 | 2004-07-08 | Atherogenics, Inc. | Process of making chalcone derivatives |
| CA2508947A1 (en) | 2002-12-20 | 2004-07-15 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| AU2004204692B2 (en) | 2003-01-07 | 2009-07-09 | Merck & Co., Inc. | Macrocyclic beta-secretase inhibitors for treatment of Alzheimer's disease |
| WO2004064778A2 (en) | 2003-01-17 | 2004-08-05 | Merck & Co. Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| US7388019B2 (en) | 2003-01-31 | 2008-06-17 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| MXPA05008156A (es) | 2003-02-01 | 2005-09-30 | Neuralab Ltd | Inmunizacion activa para generar anticuerpos para beta-a soluble. |
| ATE402934T1 (de) | 2003-02-04 | 2008-08-15 | Hoffmann La Roche | Malonamidderivate als gamma-secretaseinhibitoren |
| US7575747B2 (en) | 2003-02-10 | 2009-08-18 | Applied Molecular Evolution | Aβ binding molecules |
| WO2004071454A2 (en) | 2003-02-13 | 2004-08-26 | Guilford Pharmaceuticals Inc. | Substituted azetidine compounds as inhibitors of dipeptidyl peptidase iv |
| AU2004212965A1 (en) | 2003-02-18 | 2004-09-02 | Roskamp Research Llc | Anti-angiogenic and anti-tumoral properties of beta and gamma secretase inhibitors |
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| AU2003207881A1 (en) | 2003-02-28 | 2004-09-17 | Aic | Dipeptidyl peptidase inhibitors |
| WO2004076434A1 (en) | 2003-02-28 | 2004-09-10 | Aic | Dipeptidyl peptidase inhibitors |
| EP1454627A1 (en) | 2003-03-06 | 2004-09-08 | MyoContract Ltd. | Alpha-Keto carbonyl calpain inhibitors |
| WO2004084830A2 (en) | 2003-03-21 | 2004-10-07 | Buck Institute | Method for treating alzheimer’s dementia |
| US20040191334A1 (en) | 2003-03-24 | 2004-09-30 | Pang-Chui Shaw | Use of transhinone derivates as cholinesterase inhibitors in treating related diseases |
| CA2518465A1 (en) | 2003-03-25 | 2004-10-14 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| JP2006521399A (ja) | 2003-03-28 | 2006-09-21 | アカディア ファーマシューティカルズ，インコーポレーテッド | 疼痛管理用ムスカリンｍ１受容体アゴニスト |
| EP1613657A2 (en) | 2003-03-28 | 2006-01-11 | Centocor, Inc. | Anti-amyloid antibodies, compositions, methods and uses |
| PT1611144E (pt) | 2003-04-09 | 2010-11-12 | Wyeth Llc | Derivados do ácido 2-(8,9-dioxo-2,6-diazabiciclo(5.2.0)- non-1(7)-eno-2-il)-alquil-fosfónico e sua utilização como antagonistas do receptor n-metil-d-aspartato (nmda) |
| GB0308382D0 (en) | 2003-04-10 | 2003-05-21 | Univ Cambridge Tech | Therapeutic methods and means |
| GB0308318D0 (en) | 2003-04-10 | 2003-05-14 | Merck Sharp & Dohme | Therapeutic agents |
| WO2004089362A1 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | 2-cyanopyrroles and their analogues as ddp-iv inhibitors |
| US20040229848A1 (en) | 2003-05-05 | 2004-11-18 | Hans-Ulrich Demuth | Glutaminyl based DP IV-inhibitors |
| JP4806628B2 (ja) | 2003-05-05 | 2011-11-02 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤 |
| MXPA05011861A (es) | 2003-05-05 | 2006-02-17 | Probiodrug Ag | Uso de efectores de ciclasas de glutamato y glutaminil. |
| ES2246105B1 (es) | 2003-05-08 | 2007-03-01 | Araclon Biotech, S.L. | Uso de anticuerpos para el tratamiento de enfermedades amiloideas. |
| AU2003902260A0 (en) | 2003-05-09 | 2003-05-29 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
| ATE401328T1 (de) | 2003-05-13 | 2008-08-15 | Schering Corp | Verbrückte n-arylsulfonylpiperidine als gamma- sekretaseinhibitoren |
| ATE447574T1 (de) | 2003-05-14 | 2009-11-15 | Merck & Co Inc | 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes |
| US7638638B2 (en) | 2003-05-14 | 2009-12-29 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| KR20060013404A (ko) | 2003-05-16 | 2006-02-09 | 머크 샤프 앤드 돔 리미티드 | γ-세크레타제 억제용 사이클릭 설폰아미드 |
| MXPA05012493A (es) | 2003-05-27 | 2006-05-25 | Forest Laboratories | Combinacion de un antagonista del receptor de nmda y un inhibidor selectivo de reabsorcion de serotonina para el tratamiento de depresion y otros trastornos de estado de animo. |
| PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
| AU2003902828A0 (en) | 2003-06-05 | 2003-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
| US7332520B2 (en) | 2003-06-06 | 2008-02-19 | Merck & Co., Inc. | Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| AU2003902946A0 (en) | 2003-06-12 | 2003-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
| AU2004249163A1 (en) | 2003-06-17 | 2004-12-29 | Merck & Co., Inc. | Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| BRPI0411713B8 (pt) | 2003-06-20 | 2021-05-25 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e sua utilização |
| BRPI0411509A (pt) | 2003-06-20 | 2006-07-25 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e sua utilização |
| JP2007516207A (ja) | 2003-06-30 | 2007-06-21 | メルク エンド カムパニー インコーポレーテッド | アルツハイマー病の治療のためのＮ−アルキルフェニルカルボキサミドβ−セクレターゼ阻害剤 |
| CN101415724B (zh) | 2003-06-30 | 2015-12-02 | 特拉维夫大学未来科技开发有限公司 | 肽、抗肽抗体以及用它们来诊断和治疗淀粉样蛋白相关疾病的方法 |
| US7348448B2 (en) | 2003-07-01 | 2008-03-25 | Merck & Co., Inc. | Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease |
| WO2005007614A1 (en) | 2003-07-03 | 2005-01-27 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services 6011 | Monoamine oxidase inhibitors |
| JP2007528862A (ja) | 2003-07-16 | 2007-10-18 | アールブイエックス セラピューティクス， インコーポレイテッド | ＴＧＦ−βの効果を下方制御するための化合物および方法 |
| EP1671129A1 (en) | 2003-07-21 | 2006-06-21 | Angiogenetics Sweden AB | Compounds and methods for promoting angiogenesis by using a gamma-secretase inhibitor or inhibiting the gamma-secretase pathway |
| AU2004258751C1 (en) | 2003-07-28 | 2008-07-17 | Merz Pharma Gmbh & Co. Kgaa | The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity |
| AU2004261186A1 (en) | 2003-07-31 | 2005-02-10 | Merck & Co., Inc. | Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| WO2005011599A2 (en) | 2003-08-01 | 2005-02-10 | Northwestern University | Antibodies specific for toxic amyloid beta protein oligomers |
| GB0318447D0 (en) | 2003-08-05 | 2003-09-10 | Merck Sharp & Dohme | Therapeutic agents |
| KR20060041309A (ko) | 2003-08-13 | 2006-05-11 | 다케다 야쿠힌 고교 가부시키가이샤 | ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도 |
| CA2535337A1 (en) | 2003-08-14 | 2005-03-03 | Merck & Co., Inc. | Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease |
| WO2005018424A2 (en) | 2003-08-18 | 2005-03-03 | Research Foundation For Mental Hygiene, Inc. | Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits |
| WO2005023762A1 (en) | 2003-09-04 | 2005-03-17 | Abbott Laboratories | Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv) |
| WO2005023858A1 (en) | 2003-09-05 | 2005-03-17 | Cellzome Ag | Protein complexes associated with app-processing |
| WO2005030751A2 (en) | 2003-09-08 | 2005-04-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| JP2007505121A (ja) | 2003-09-08 | 2007-03-08 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
| AR046330A1 (es) | 2003-09-09 | 2005-12-07 | Japan Tobacco Inc | Inhibidor de dipeptidilpeptidasa iv |
| WO2005025616A1 (ja) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | 抗体の用途 |
| AU2004272112A1 (en) | 2003-09-12 | 2005-03-24 | The Regents Of The University Of California | Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates |
| GB0322140D0 (en) | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
| WO2005030731A1 (en) | 2003-09-24 | 2005-04-07 | Merck Sharp & Dohme Limited | Gamma-secretase inhibitors |
| AU2004277981B2 (en) | 2003-10-03 | 2009-10-01 | Merck & Co., Inc. | Benzylether and benzylamino beta-secretase inhibitors for the treatment of Alzheimer's disease |
| PT1673347E (pt) | 2003-10-06 | 2015-11-02 | Hoffmann La Roche | Derivados de dibenzo-azepina e benzo-diazepina substituídos, úteis como inibidores de secretase gama |
| JP2007516154A (ja) | 2003-10-06 | 2007-06-21 | トレント・ファーマシューティカルズ・リミテッド | アゾリジンカーボニトリル類及びそれらのｄｐｐ−ｉｖ阻害剤としての用途 |
| BRPI0415109A (pt) | 2003-10-08 | 2006-11-28 | Pfizer | compostos de 1-[2-(4-hidroxifenil)-2-hidroxietil]-piperidin-4-ol como antagonistas de receptor de nmda |
| CA2542419C (en) | 2003-10-15 | 2013-06-04 | Probiodrug Ag | Use of glutamyl cyclase inhibitors in the treatment of familial british dementia and familial danish dementia |
| EP2269608A3 (en) | 2003-10-16 | 2011-02-16 | NeuroSearch AS | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor |
| GB0324236D0 (en) | 2003-10-16 | 2003-11-19 | Astrazeneca Ab | Chemical compounds |
| TW200519105A (en) | 2003-10-20 | 2005-06-16 | Lg Life Science Ltd | Novel inhibitors of DPP-IV, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent |
| US20050113458A1 (en) | 2003-10-22 | 2005-05-26 | Forest Laboratories, Inc. | Use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic a-beta peptides in amyloidopathies |
| EP1824846A2 (en) | 2003-11-03 | 2007-08-29 | Probiodrug AG | Novel compounds for the treatment of neurological disorders |
| WO2005044195A2 (en) | 2003-11-04 | 2005-05-19 | Merck & Co., Inc. | Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| JP4451449B2 (ja) | 2003-11-11 | 2010-04-14 | エフ．ホフマン−ラ ロシュ アーゲー | ホスフィン酸誘導体、アルツハイマー病の処置のためのベータセクレターゼインヒビタ |
| EP1689757B1 (en) | 2003-11-12 | 2014-08-27 | Phenomix Corporation | Heterocyclic boronic acid compounds |
| WO2005051914A1 (en) | 2003-11-24 | 2005-06-09 | Merck & Co., Inc. | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease |
| DE10355304A1 (de) | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| UY28650A1 (es) | 2003-12-05 | 2005-02-28 | Forest Laboratories | Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta |
| EP1541143A1 (en) | 2003-12-09 | 2005-06-15 | Graffinity Pharmaceuticals Aktiengesellschaft | Dpp-iv inhibitors |
| EP1541148A1 (en) | 2003-12-09 | 2005-06-15 | Graffinity Pharmaceuticals Aktiengesellschaft | Dpp-iv inhibitors |
| WO2005058849A1 (en) | 2003-12-15 | 2005-06-30 | Glenmark Pharmaceuticals Ltd. | New dipeptidyl peptidase in inhibitors; process for their preparation and compositions containing them |
| WO2005065195A2 (en) | 2003-12-19 | 2005-07-21 | Merck & Co., Inc. | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease |
| WO2005070429A1 (en) | 2004-01-22 | 2005-08-04 | Neurosearch A/S | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist |
| WO2005072705A1 (en) | 2004-01-29 | 2005-08-11 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions |
| WO2005075426A1 (en) | 2004-02-03 | 2005-08-18 | Glenmark Pharmaceuticals Ltd. | Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof |
| KR101099206B1 (ko) | 2004-02-05 | 2011-12-27 | 프로비오드룩 아게 | 신규한 글루타미닐 시클라제 저해제 |
| EP1734920A2 (en) | 2004-02-13 | 2006-12-27 | Neuromolecular Inc. | Combination of a nmda receptor antagonist and an mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions |
| US20050182044A1 (en) | 2004-02-17 | 2005-08-18 | Bruinsma Gosse B. | Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate |
| CA2555050C (en) | 2004-02-18 | 2017-11-28 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthine derivatives, the production thereof and the use in the form of a dpp-iv inhibitor |
| WO2005080435A1 (ja) | 2004-02-20 | 2005-09-01 | Immuno-Biological Laboratories Co., Ltd. | モノクローナル抗体およびその利用 |
| KR101292707B1 (ko) | 2004-02-23 | 2013-08-02 | 트러스티즈 오브 터프츠 칼리지 | 디펩티딜펩티다아제 ⅳ의 억제제 |
| EP1593671A1 (en) | 2004-03-05 | 2005-11-09 | Graffinity Pharmaceuticals AG | DPP-IV inhibitors |
| EP1729774A4 (en) | 2004-03-09 | 2009-05-06 | Nat Health Research Institutes | PYRROLIDINE CONNECTIONS |
| EA013427B1 (ru) | 2004-03-15 | 2010-04-30 | Такеда Фармасьютикал Компани Лимитед | Ингибиторы дипептидилпептидазы |
| US20070213388A1 (en) | 2004-03-19 | 2007-09-13 | Bruinsma Gosse B | Acetylcholinesterase Inhibitors and N-Methyl-D-Aspartate Antagonists Useful in the Treatment of of Cognitive Disorders |
| WO2005095339A1 (en) | 2004-03-31 | 2005-10-13 | Pfizer Products Inc. | Dicyanopyrrolidines as dipeptidyl peptidase iv inhibitors |
| WO2005097103A2 (en) | 2004-04-01 | 2005-10-20 | Axys Pharmaceuticals, Inc. | Diabetes and metabolic syndrome therapy utilizing cathepsin b inhibitors |
| KR20070010144A (ko) | 2004-04-05 | 2007-01-22 | 쉐링 코포레이션 | 신규한 감마 세크레타제 억제제 |
| CA2563615A1 (en) | 2004-04-20 | 2005-11-03 | Merck & Co., Inc. | 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
| AU2005236063A1 (en) | 2004-04-20 | 2005-11-03 | Merck & Co., Inc. | 2, 4, 6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease |
| WO2005102390A2 (en) | 2004-04-22 | 2005-11-03 | Pfizer Japan, Inc. | Combinations comprising alpha-2-delta ligands and nmda receptor antagonists |
| US9549895B2 (en) | 2004-04-23 | 2017-01-24 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving the viability of photoreceptor cells |
| US7763249B2 (en) | 2004-04-27 | 2010-07-27 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Human anti-amyloid β peptide antibody and fragment of said antibody |
| CA2564264A1 (en) | 2004-05-04 | 2005-11-17 | Merck & Co., Inc. | 1,2,4-oxadiazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| EP1753748B1 (en) | 2004-05-12 | 2009-07-29 | Pfizer Products Inc. | Proline derivatives and their use as dipeptidyl peptidase iv inhibitors |
| AU2005245376A1 (en) | 2004-05-13 | 2005-12-01 | Merck & Co., Inc. | Phenyl carboxamide compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease |
| JP2007538079A (ja) | 2004-05-18 | 2007-12-27 | メルク エンド カムパニー インコーポレーテッド | 糖尿病の治療又は予防のためのジペプチジルペプチダーゼ−ｉｖ阻害剤としてのシクロヘキシルアラニン誘導体 |
| EP1598341A1 (en) | 2004-05-21 | 2005-11-23 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | DPP-IV inhibitors |
| JP2008501714A (ja) | 2004-06-04 | 2008-01-24 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼインヒビター |
| CA2568914C (en) | 2004-06-04 | 2013-09-24 | Affinium Pharmaceuticals, Inc. | Therapeutic agents, and methods of making and using the same |
| EP1766396B1 (en) | 2004-06-07 | 2010-08-11 | Ramot at Tel-Aviv University Ltd. | Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation |
| EP1604662A1 (en) | 2004-06-08 | 2005-12-14 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus |
| EP1604980A1 (en) | 2004-06-08 | 2005-12-14 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | DPP-IV inhibitors |
| EP1604989A1 (en) | 2004-06-08 | 2005-12-14 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | DPP-IV inhibitors |
| US7714021B2 (en) | 2004-06-15 | 2010-05-11 | Merck & Co., Inc. | Pyrrolidin-3-yl compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease |
| GB0413389D0 (en) | 2004-06-16 | 2004-07-21 | Astrazeneca Ab | Chemical compounds |
| WO2006009886A1 (en) | 2004-06-21 | 2006-01-26 | Merck & Co., Inc. | Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| US7371825B2 (en) | 2004-06-30 | 2008-05-13 | Centocor, Inc. | Anti-MCP-1 antibodies, compositions, methods and uses |
| CN101602741A (zh) | 2004-06-30 | 2009-12-16 | 先灵公司 | 作为γ-分泌酶抑制剂的取代的N-芳基磺酰基杂环胺 |
| EP1769002A1 (en) | 2004-07-02 | 2007-04-04 | Northwestern University | Monolocal antibodies that target pathological assemblies of amyloid beta; (abeta) |
| CA2573848A1 (en) | 2004-07-12 | 2006-02-16 | Phenomix Corporation | Constrained cyano compounds |
| WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| WO2006014638A2 (en) | 2004-07-19 | 2006-02-09 | The General Hospital Corporation | ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS |
| WO2006008661A2 (en) | 2004-07-19 | 2006-01-26 | Neurochem (International) Limited | Diagnostic methods of multiple organ amyloidosis |
| ATE491693T1 (de) | 2004-07-22 | 2011-01-15 | Schering Corp | Substituierte amide als inhibitoren der beta- sekretase |
| WO2006014944A1 (en) | 2004-07-28 | 2006-02-09 | Schering Corporation | Macrocyclic beta-secretase inhibitors |
| HUP0401523A3 (en) | 2004-07-29 | 2007-05-02 | Richter Gedeon Vegyeszet | Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them |
| GEP20115195B (en) | 2004-07-30 | 2011-04-11 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and use thereof |
| EP1623983A1 (en) | 2004-08-05 | 2006-02-08 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | Heterocyclic compounds useful as DPP-IV inhibitors |
| US8168188B1 (en) | 2004-08-11 | 2012-05-01 | Kyoto University | Antibody and utilization of the same |
| CA2576465A1 (en) | 2004-08-23 | 2006-03-02 | Merck & Co., Inc. | Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| EP1781687A1 (en) | 2004-08-25 | 2007-05-09 | Santhera Pharmaceuticals (Schweiz) AG | Alpha-keto carbonyl calpain inhibitors |
| AU2005276635A1 (en) | 2004-08-25 | 2006-03-02 | Santhera Pharmaceuticals (Schweiz) Ag | Alpha-keto carbonyl calpain inhibitors |
| US7388007B2 (en) | 2004-08-26 | 2008-06-17 | Bristol-Myers Squibb Company | Gamma-lactams as beta-secretase inhibitors |
| TWI374935B (en) | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
| WO2006029850A1 (en) | 2004-09-14 | 2006-03-23 | The Genetics Company, Inc. | Hydrazone derivatives and their use as beta secretase inhibitors |
| US7659289B2 (en) | 2004-09-17 | 2010-02-09 | Comentis, Inc. | Hydroxyethylene-based β-secretase inhibitors and use thereof |
| WO2006034277A1 (en) | 2004-09-17 | 2006-03-30 | Comentis, Inc. | Bicyclic compounds which inhibit beta-secretase activity and methods of use thereof |
| EP1799260A4 (en) | 2004-09-29 | 2011-09-28 | Centocor Inc | ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, TECHNIQUES AND USES |
| EP1796669B1 (en) | 2004-10-01 | 2010-09-22 | Merck Sharp & Dohme Corp. | Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| WO2006042103A2 (en) | 2004-10-05 | 2006-04-20 | Axys Pharmaceuticals, Inc. | Reversible inhibitors of cathepsin b |
| AU2005294320A1 (en) | 2004-10-08 | 2006-04-20 | Novartis Ag | Combination of organic compounds |
| US9186345B2 (en) | 2004-10-12 | 2015-11-17 | Hakon Hakonarson | Method of treating skin diseases |
| CA2583342A1 (en) | 2004-10-13 | 2006-04-27 | Merck And Co., Inc. | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer's disease |
| EP1807066A1 (en) | 2004-10-25 | 2007-07-18 | Novartis AG | Combination of dpp-iv inhibitor, ppar antidiabetic and metformin |
| AU2005306997B2 (en) | 2004-10-25 | 2012-07-05 | Merck Sharp & Dohme Corp. | Anti-ADDL antibodies and uses thereof |
| US20080199879A1 (en) | 2004-10-28 | 2008-08-21 | Sanko Junyaku Co., Ltd. | Method of Assaying Alzheimer's Disease and Diagnostic Reagent |
| US7932275B2 (en) | 2004-10-29 | 2011-04-26 | Merck, Sharp & Dohme Corp. | 2-aminopyridine compounds useful as β-secretase inhibitors for the treatment of alzheimer's disease |
| JP2008520670A (ja) | 2004-11-17 | 2008-06-19 | メルク エンド カムパニー インコーポレーテッド | アルツハイマー病の治療のための大環状第三アミンβ−セクレターゼ阻害剤 |
| WO2006057945A2 (en) | 2004-11-23 | 2006-06-01 | Merck & Co., Inc. | 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
| CA2588295C (en) | 2004-11-23 | 2013-10-22 | Adamas Pharma, Llc | Method and composition for administering an nmda receptor antagonist to a subject |
| AU2005309708A1 (en) | 2004-11-23 | 2006-06-01 | Merck & Co., Inc. | Macrocyclic aminopyridyl beta-secretase inhibitors for the treatment of Alzheimer's disease |
| CA2588296A1 (en) | 2004-11-24 | 2006-06-01 | Neuromolecular Pharmaceuticals, Inc. | Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease |
| EP1819674B1 (en) | 2004-11-29 | 2011-10-05 | Merck Sharp & Dohme Corp. | Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| JP4842963B2 (ja) | 2004-11-30 | 2011-12-21 | エフ．ホフマン−ラ ロシュ アーゲー | 糖尿病を処置するｄｐｐ−ｉｖ阻害剤としての置換ベンゾキノリジン |
| WO2006060473A2 (en) | 2004-12-03 | 2006-06-08 | Mucosal Therapeutics Llc | Methods of treatment of injured or diseased joints with lubricin compositions |
| WO2006066233A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | An immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies |
| PE20061329A1 (es) | 2004-12-15 | 2006-12-08 | Neuralab Ltd | Anticuerpos ab humanizados para mejorar la cognicion |
| ES2396555T3 (es) | 2004-12-15 | 2013-02-22 | Janssen Alzheimer Immunotherapy | Anticuerpos que reconocen péptido beta amiloide |
| US20060257396A1 (en) | 2004-12-15 | 2006-11-16 | Jacobsen Jack S | Abeta antibodies for use in improving cognition |
| US7411093B2 (en) | 2004-12-20 | 2008-08-12 | Hoffman-La Roche Inc. | Aminocycloalkanes as DPP-IV inhibitors |
| CN101090888A (zh) | 2004-12-20 | 2007-12-19 | 霍夫曼-拉罗奇有限公司 | 4－氨基哌啶衍生物 |
| EP1828192B1 (en) | 2004-12-21 | 2014-12-03 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2006071274A2 (en) | 2004-12-23 | 2006-07-06 | Voyager Pharmaceutical Corporation | Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease |
| WO2006070394A1 (en) | 2004-12-28 | 2006-07-06 | Council Of Scientific And Industrial Research | Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors |
| US20080194548A1 (en) | 2005-01-06 | 2008-08-14 | Forrest Michael J | Drug Combination Therapy and Pharmaceutical Compositions for Treating Inflammatory Disorders |
| CA2594943A1 (en) | 2005-01-19 | 2006-07-27 | Merck & Co., Inc. | Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease |
| CA2589860A1 (en) | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
| US20060216331A1 (en) | 2005-02-28 | 2006-09-28 | Lines Thomas C | Composition for treating mental health disorders |
| WO2006094674A1 (en) | 2005-03-07 | 2006-09-14 | Michael Hermanussen | Nmda receptor antagonists in the medical intervention of metabolic disorders |
| ES2259270B1 (es) | 2005-03-09 | 2007-11-01 | Consejo Superior De Investigaciones Cientificas | Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal. |
| WO2006099352A1 (en) | 2005-03-10 | 2006-09-21 | Bristol-Myers Squibb Company | Novel isophthalates as beta-secretase inhibitors |
| FR2883285B1 (fr) | 2005-03-17 | 2007-05-18 | Sanofi Aventis Sa | Sel besylate de la 7-(2-(4-(3-trifluoromethyl-phenyl) -1,2,3,6-tetrahudro-pyrid-1-yl)ethyl) isoquinoleine, sa preparation et son utilisation en therapeutique |
| ES2318918B1 (es) | 2005-04-01 | 2010-02-16 | Biotherapix Molecular Medicines, S.L.U. | Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones. |
| KR20080000624A (ko) | 2005-04-27 | 2008-01-02 | 노파르티스 아게 | 아테롬성동맥경화증의 치료 방법 |
| PE20061323A1 (es) | 2005-04-29 | 2007-02-09 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos |
| TWI410406B (zh) * | 2005-05-13 | 2013-10-01 | Otsuka Pharma Co Ltd | 吡咯烷化合物 |
| PE20061444A1 (es) | 2005-05-19 | 2007-01-15 | Centocor Inc | Anticuerpo anti-mcp-1, composiciones, metodos y usos |
| EP1921137A4 (en) | 2005-06-21 | 2011-01-26 | Med & Biological Lab Co Ltd | ANTIBODIES WITH INHIBITOR EFFECT ON THE FORMATION OF AMYLOID FIBRILLES |
| EP1904061B1 (en) * | 2005-06-23 | 2018-12-26 | Array Biopharma, Inc. | SNAr PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS |
| MX2008007477A (es) | 2005-12-12 | 2008-09-03 | Ac Immune Sa | Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas. |
| SG172617A1 (en) | 2005-12-12 | 2011-07-28 | Ac Immune Sa | Therapeutic vaccine |
| GB0704100D0 (en) | 2006-03-17 | 2007-04-11 | Vodafone Plc | Improvements in an ehspa architecture |
| NZ574188A (en) | 2006-07-14 | 2012-05-25 | Ac Immune Sa | Humanized antibody against amyloid beta |
| EP2091945B1 (en) | 2006-11-09 | 2014-01-15 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| US7741354B2 (en) | 2006-11-09 | 2010-06-22 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| JP5523107B2 (ja) | 2006-11-30 | 2014-06-18 | プロビオドルグ エージー | グルタミニルシクラーゼの新規阻害剤 |
| WO2008128985A1 (en) * | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
-
2011
- 2011-04-21 WO PCT/EP2011/056396 patent/WO2011131748A2/en not_active Ceased
- 2011-04-21 US US13/091,276 patent/US8541596B2/en active Active
- 2011-04-21 EP EP11715924.4A patent/EP2560953B1/en active Active
- 2011-04-21 JP JP2013505486A patent/JP5945532B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013525334A (ja) | 2013-06-20 |
| EP2560953B1 (en) | 2016-01-06 |
| EP2560953A2 (en) | 2013-02-27 |
| US20110262388A1 (en) | 2011-10-27 |
| US8541596B2 (en) | 2013-09-24 |
| WO2011131748A2 (en) | 2011-10-27 |
| WO2011131748A3 (en) | 2012-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5688745B2 (ja) | グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤 | |
| JP5675340B2 (ja) | 新規阻害剤 | |
| JP5612860B2 (ja) | グルタミニルシクラーゼ阻害剤としてのイミダゾ［１，５−ａ］ピリジン誘導体 | |
| JP6026284B2 (ja) | グルタミニルシクラーゼの阻害剤 | |
| JP5667440B2 (ja) | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 | |
| JP5707327B2 (ja) | 新規の阻害剤 | |
| JP5675343B2 (ja) | グルタミニルシクラーゼ阻害剤としての尿素誘導体 | |
| JP5675342B2 (ja) | グルタミニルシクラーゼ阻害剤としてのシアノグアニジン誘導体 | |
| JP5675344B2 (ja) | グルタミニルシクラーゼ阻害剤としてのニトロビニルジアミン誘導体 | |
| JP6050264B2 (ja) | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 | |
| EP2560953B1 (en) | Inhibitors of glutaminyl cyclase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140416 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140416 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150512 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150803 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151111 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160510 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160530 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5945532 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |